Sandoz Group AG (XSWX:SDZ) Current Accrued Expense: CHF0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:SDZ Sandoz Group AG XSWX:SDZ
27 GF Score
Price CHF72.78
GF Value CHF47.46
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sandoz Group AG Current Accrued Expense?

Sandoz Group AG XSWX:SDZ +5.20% 27 Current Accrued Expense is CHF0 Mil as of Jun. 2026. GuruFocus rates XSWX:SDZ with a GF Score™ of 27/100 and a GF Value™ of CHF47.46 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Sandoz Group AG's Current Accrued Expense for the quarter that ended in Jun. 2026 was CHF0 Mil.

Sandoz Group AG Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG Current Accrued Expense Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
0.00 0.00 0.00 0.00

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Accrued Expense Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
XSWX:SDZ
27GF Score
Sandoz Group AG XSWX:SDZ
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandoz Group AG Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of CHF0 Mil mean?
Sandoz Group AG (XSWX:SDZ) has a Current Accrued Expense of CHF0 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Current Accrued Expense too high?
Sandoz Group AG's current Current Accrued Expense is CHF0 Mil. Overall, Sandoz Group AG has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Current Accrued Expense compare to ZTS and UTHR?
Sandoz Group AG's Current Accrued Expense of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Current Accrued Expense is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Based on GuruFocus' analysis, Sandoz Group AG (XSWX:SDZ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF47.46, compared to a current price of CHF72.78 — trading 53.4% above its estimated fair value. The current Current Accrued Expense is CHF0 Mil. Sandoz Group AG's overall GF Score™ is 27/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Current Accrued Expense is CHF0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sandoz Group AG (XSWX:SDZ) Overvalued in 2026?

Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued. The current stock price of CHF72.78 is trading 53.4% above its estimated GF Value™ of CHF47.46. GuruFocus considers Sandoz Group AG to be Significantly Overvalued.

Key valuation signals for XSWX:SDZ:

  • Current Accrued Expense: CHF0 Mil
  • GF Value™: CHF47.46 vs. price of CHF72.78 (53.4% above fair value)
  • GF Score™: 27/100 with 6 warning signs

No single metric tells the full story. See the XSWX:SDZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
27GF Score

Get the complete analysis for XSWX:SDZ

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF72.78
Price
CHF47.46
GF Value